A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry and neurology collaboration spanning four drugs discovered by an artificial intelligence technology platform.
The companies will partner on development and commercialization of ARO-AAT, Arrowhead's Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda's position in the AAT-augmentation therapy market.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Results of the study of Ninlaro in newly diagnosed patients ineligible for transplant did not reach statistical significance. The announcement came a day after Bristol-Myers Squibb announced the failure of a study in the same disease setting.